Decode Health Collaborates with Quest Diagnostics to Speed Biomarker Discovery for Drug and Diagnostics Development

Rhea-AI Summary

Decode Health announced a new collaboration phase with Quest Diagnostics (NYSE: DGX) to advance drug and diagnostics research in metabolic disease and autoimmune neurology. This phase will focus on RNA sequencing and specimen collection through Quest's extensive network, including 2,100 patient service centers. The partnership aims to enhance biomarker discovery, crucial for developing novel diagnostic tests and drug therapies. The initial targets include multiple sclerosis and non-alcoholic fatty liver disease, with plans for future expansion into other clinical areas.

Positive

• Collaboration to enhance drug and diagnostics research in metabolic diseases and autoimmune neurology.
• Development of a national platform for RNA sequencing and specimen collection, leveraging 2,100 patient service centers.
• Focus on biomarker discovery to accelerate the development of novel diagnostics and therapeutics.

Negative

• None.

Features Nationally Scaled RNA Sequencing and Specimen Collection for Multiple Sclerosis and Non-Alcoholic Fatty Liver Disease with Plans to Expand

NASHVILLE, Tenn., Oct. 18, 2022 /PRNewswire/ -- Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.

Our work will create opportunities to fuel critical advances that unlock cutting-edge diagnostics and therapeutics.

In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. In this latest phase, the parties have developed a national platform for collecting and storing deidentified consented specimens from individuals participating in research sponsored by pharmaceutical, academic research and patient engagement organizations. The platform includes Quest's 2,100 patient service centers as well as its ExamOne mobile in-home phlebotomy team and a biobank at its advanced laboratory in Memphis, Tenn.

The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets. Nearly 60% of clinical trials include strategies to identify treatment biomarkers.^[i] As part of the collaboration, Quest and Decode will share benefits from any research, data licensing, biomarker discovery or diagnostics development that emerge. Additional terms were not disclosed.

"RNA analysis holds the potential to ignite the next generation of diagnostics and drug targets for MS and other metabolic and autoimmune neurological disorders," said Jay G. Wohlgemuth, MD, Senior Vice President R&D and Chief Medical Officer, Quest Diagnostics. "To optimize this potential, Quest with Decode Health and other collaborators is mobilizing a nationally scaled sequencing, research and patient engagement platform to empower life science organizations to hasten these discoveries and bring precision medicine to life for patients in the U.S. and globally.

At this stage of the collaboration, Decode and Quest's initial focus is on addressing a pressing need for earlier detection, differential diagnosis and therapy selection for multiple sclerosis (MS), which affects about 2.8 million worldwide,^[ii]and non-alcoholic fatty liver disease (NAFLD), a metabolic disorder and the most common cause of liver disease worldwide.^[iii] Both disorders can be challenging to diagnose, especially at their early stages; MS does not always respond to existing therapies, and NAFLD currently does not have standard therapies available. As the collaboration progresses, the parties plan to expand to additional clinical disease areas.

"Opportunities to significantly improve healthcare are hidden within data, especially for diagnostic and drug discoveries," said Chase Spurlock, PhD, Co-founder and CEO of Decode Health. "The work we are doing today with Quest Diagnostics aims to unlock those discoveries. Every day, we are building upon our collective goal to advance precision medicine and improve health outcomes across a growing number of conditions. By collaborating with key healthcare stakeholders, including pharma, we believe that our work will create opportunities to fuel critical advances that unlock the next generation of cutting-edge diagnostics and therapeutics."

About Decode Health

Decode Health is a healthcare AI company that powers an ecosystem of industry-leading diagnostic and pharmaceutical companies to unlock discoveries with data. Current projects include genomic data creation, RNA diagnostics, and population health analytics. Over the course of a decade, the team leading Decode has built a framework leveraging a variety of advanced machine learning approaches. The company's flexible, scalable approach layers clinical data with SDoH and non-clinical data to fuel innovation and advance precision medicine. Decode's data assets, products, and services improve patient outcomes, lower costs, and promote health equity. For more information, visit www.DecodeHealth.ai.

Media Contacts
For Decode Health:
Nikki Cary
nikki.cary@decodehealth.ai
615.500.2924

For Quest Diagnostics:
Jennifer Petrella
mediacontact@questdiagnostics.com
973.520.2800

[i] Pharma Precision Medicine Readiness Report 2019 Supplemental Update: Analysis of FDA 2019 Test-Dependent Therapy Approvals - Diaceutics
[ii] Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition - PMC (nih.gov)
[iii] Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD | Scientific Reports (nature.com)

View original content:https://www.prnewswire.com/news-releases/decode-health-collaborates-with-quest-diagnostics-to-speed-biomarker-discovery-for-drug-and-diagnostics-development-301651333.html

SOURCE Decode Health

FAQ

What is the collaboration between Decode Health and Quest Diagnostics focused on?

The collaboration focuses on advancing research in metabolic disease and autoimmune neurology through RNA sequencing and specimen collection.

What diseases are Decode Health and Quest Diagnostics initially targeting with their collaboration?

They are focusing on multiple sclerosis and non-alcoholic fatty liver disease.

How many patient service centers does Quest Diagnostics have for this collaboration?

Quest Diagnostics has 2,100 patient service centers utilized for specimen collection.

What are the potential benefits of the Decode Health and Quest Diagnostics collaboration?

The collaboration aims to reduce the time and cost of developing novel diagnostic tests and identifying new drug targets.

When was the collaboration between Decode Health and Quest Diagnostics announced?

The collaboration was announced on October 18, 2022.